Ken Griffin Exact Sciences Corp Transaction History

Citadel Advisors LLC

$509 Billion
Q1 2024

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Exact Sciences Corp stock. As of the latest transaction made, Citadel Advisors LLC holds 735,200 shares of EXAS stock, worth $30.8 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

735,200

Previous 259,500 183.31%

Holding current value

$30.8 Million

Previous $19.2 Million 164.48%

% of portfolio

0.01%

Previous 0.0%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$56.27 - $73.77 $38.6 Million - $50.6 Million	-685,487 Reduced 25.02%	2,054,197 $142 Million
Q4 2023 Feb 14, 2024	BUY	$59.06 - $75.72 $61.6 Million - $79 Million	1,043,452 Added 61.52%	2,739,684 $203 Million
Q3 2023 Nov 14, 2023	SELL	$65.94 - $99.04 $49.2 Million - $73.8 Million	-745,502 Reduced 30.53%	1,696,232 $116 Million
Q2 2023 Aug 14, 2023	BUY	$62.68 - $95.05 $47.7 Million - $72.4 Million	761,728 Added 45.34%	2,441,734 $229 Million
Q1 2023 May 15, 2023	BUY	$47.19 - $70.77 $20.5 Million - $30.8 Million	434,876 Added 34.93%	1,680,006 $114 Million

Q4 2022 Feb 14, 2023	SELL	$30.35 - $53.15 $1.98 Million - $3.47 Million	-65,193 Reduced 4.98%	1,245,130 $61.6 Million
Q3 2022 Nov 14, 2022	SELL	$31.97 - $49.37 $39 Million - $60.2 Million	-1,219,387 Reduced 48.2%	1,310,323 $42.6 Million
Q2 2022 Aug 15, 2022	BUY	$35.61 - $76.23 $89.4 Million - $191 Million	2,509,427 Added 12372.07%	2,529,710 $99.6 Million
Q1 2022 May 16, 2022	SELL	$57.56 - $82.54 $13.6 Million - $19.5 Million	-236,699 Reduced 92.11%	20,283 $1.42 Million
Q4 2021 Feb 14, 2022	SELL	$72.5 - $100.68 $23 Million - $31.9 Million	-317,189 Reduced 55.24%	256,982 $20 Million
Q3 2021 Nov 15, 2021	BUY	$90.24 - $124.05 $43.3 Million - $59.5 Million	479,305 Added 505.24%	574,171 $54.8 Million
Q2 2021 Aug 16, 2021	BUY	$93.66 - $139.27 $413,321 - $614,598	4,413 Added 4.88%	94,866 $11.8 Million
Q1 2021 May 17, 2021	SELL	$116.57 - $155.01 $9.42 Million - $12.5 Million	-80,849 Reduced 47.2%	90,453 $11.9 Million
Q4 2020 Feb 16, 2021	SELL	$99.61 - $142.12 $12.6 Million - $17.9 Million	-126,007 Reduced 42.38%	171,302 $22.7 Million
Q3 2020 Nov 16, 2020	SELL	$72.92 - $102.01 $61.2 Million - $85.5 Million	-838,623 Reduced 73.83%	297,309 $30.3 Million
Q2 2020 Aug 14, 2020	BUY	$55.75 - $92.75 $53.4 Million - $88.8 Million	957,741 Added 537.48%	1,135,932 $98.8 Million
Q1 2020 May 15, 2020	BUY	$37.9 - $104.44 $3.15 Million - $8.69 Million	83,228 Added 87.64%	178,191 $10.3 Million
Q4 2019 Feb 14, 2020	SELL	$77.66 - $99.74 $31.7 Million - $40.8 Million	-408,591 Reduced 81.14%	94,963 $8.78 Million
Q3 2019 Nov 14, 2019	BUY	$90.37 - $122.49 $34.2 Million - $46.3 Million	377,934 Added 300.85%	503,554 $45.5 Million
Q2 2019 Aug 14, 2019	BUY	$89.51 - $118.04 $8.06 Million - $10.6 Million	90,087 Added 253.53%	125,620 $14.8 Million
Q1 2019 May 15, 2019	SELL	$61.98 - $96.5 $12.9 Million - $20.1 Million	-207,876 Reduced 85.4%	35,533 $0
Q4 2018 Feb 14, 2019	BUY	$56.04 - $82.66 $11.2 Million - $16.5 Million	199,297 Added 451.8%	243,409 $15.4 Million
Q3 2018 Nov 13, 2018	SELL	$48.29 - $80.6 $37 Million - $61.7 Million	-765,952 Reduced 94.55%	44,112 $0
Q2 2018 Aug 10, 2018	BUY	$37.84 - $69.96 $22.1 Million - $40.9 Million	584,144 Added 258.56%	810,064 $0
Q1 2018 May 11, 2018	BUY	$39.82 - $57.53 $3.1 Million - $4.48 Million	77,944 Added 52.67%	225,920 $9.11 Million
Q4 2017 Feb 09, 2018	SELL	$46.49 - $60.51 $1.57 Million - $2.04 Million	-33,674 Reduced 18.54%	147,976 $7.78 Million
Q3 2017 Nov 09, 2017	BUY	$37.05 - $47.12 $6.73 Million - $8.56 Million	181,650	181,650 $8.56 Million

Others Institutions Holding EXAS

# of Institutions

700

Shares Held

160M

Call Options Held

5.84M

Put Options Held

2.58M

View Full List

About EXACT SCIENCES CORP

Ticker EXAS
Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 176,960,000
Market Cap $7.41B
Description
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for...

More about EXAS

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account